Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12-month consensus target price of $7.00 for the company and are expecting that the company will post ($0.17) EPS for the current quarter, according to Zacks. Zacks has also assigned Cyclacel Pharmaceuticals an industry rank of 90 out of 256 based on the ratings given to related companies.
Several research analysts have commented on the company. Zacks Investment Research downgraded Cyclacel Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 16th. Roth Capital reissued a “buy” rating on shares of Cyclacel Pharmaceuticals in a research note on Thursday, May 23rd.
NASDAQ CYCC traded down $0.02 during trading on Friday, hitting $0.42. 10,262 shares of the company’s stock were exchanged, compared to its average volume of 503,232. The company has a current ratio of 7.26, a quick ratio of 7.26 and a debt-to-equity ratio of 0.08. The company has a market cap of $7.40 million, a PE ratio of -0.68 and a beta of 3.03. Cyclacel Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $1.73. The stock’s 50 day moving average price is $0.48 and its two-hundred day moving average price is $0.65.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.01). Analysts forecast that Cyclacel Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC lifted its position in shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 82.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,102,400 shares of the biotechnology company’s stock after purchasing an additional 498,200 shares during the period. Renaissance Technologies LLC owned about 6.41% of Cyclacel Pharmaceuticals worth $596,000 as of its most recent filing with the Securities and Exchange Commission. 8.96% of the stock is currently owned by institutional investors.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Featured Story: Why is the conference call important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.